Drug Profile
Nidufexor - Novartis
Alternative Names: LMB-763Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Benzoic acids; Benzopyrans; Hepatoprotectants; Pyrazoles; Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic nephropathies
- No development reported Cholestasis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Cholestasis in USA (PO)
- 11 Mar 2021 Nidufexor is still in phase II trials for Diabetic nephropathies in USA (NCT03804879)
- 27 Aug 2020 Pharmacokinetics, adverse events and pharmacodynamics data from a phase II trial in Non-alcoholic steatohepatitis presented at the International Liver Congress 2020 (ILC-2020)